Skip to content

Intervention for Comorbid Substance Use and Bipolar Disorders

RCT to Improve Post-Hospital Treatment Adherence for Comorbid Substance Use and Bipolar Disorders

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04202393
Acronym
ITAP
Enrollment
178
Registered
2019-12-17
Start date
2020-10-21
Completion date
2025-08-31
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Substance Use Disorders

Brief summary

This trial aims to evaluate the effectiveness of a novel intervention for patients with co-occurring bipolar and substance use disorders following a psychiatric hospitalization. Half of the participants will receive a specialized psychosocial intervention program, while the other half will receive an enhanced safety monitoring program, both provided in addition to their routine care.

Interventions

BEHAVIORALIntegrated Treatment Adherence Program (ITAP)

Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.

Enhanced assessment and evaluation with clinician feedback.

Sponsors

Butler Hospital
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion: * Diagnosis of a bipolar-spectrum disorder * Diagnosis of a substance use disorder * Taking at least one mood-stabilizing medication Exclusion: * Unable to speak and read English * Younger than age 18

Design outcomes

Primary

MeasureTime frameDescription
Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)6 monthsThe Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C) assesses depressive symptom severity. Total scores range from 0 to 27 and higher scores indicated higher symptom severity.
Clinician-Administered Rating Scale for Mania (CARS-M)6 monthsThe Clinician-Administered Rating Scale for Mania (CARS-M) assesses mania symptom severity. Total scores range from 0 to 50 and higher scores indicated higher symptom severity.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBrandon Gaudiano, PhD

Butler Hospital

PRINCIPAL_INVESTIGATORIvan Miller, PhD

Butler Hospital

Participant flow

Recruitment details

Between October 2020 and November 2024, chart screens were completed for inpatient and partial hospital admissions at a local psychiatric hospital. Based on initial eligibility criteria, patients were approached on the units. Study staff described the study and, if the patient was interested, completed an informed consent process.

Pre-assignment details

After consent, participants completed a baseline assessment to confirm eligibility before random assignment. Two participants who were randomly assigned were not included in the data because they were randomized in error and were subsequently determined not to be eligible to participate. It was discovered that one had previously participated in a study with a similar intervention and another had previously participated in this study. The final intent-to-treat sample was 176.

Baseline characteristics

Characteristic
Age, Continuous38.2088 years
STANDARD_DEVIATION 12.1532
Ethnicity (NIH/OMB)
Hispanic or Latino
21 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
77 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
Quick Inventory of Depressive Symptomatology - Clinician Rating (QIDS-C)19.5 total score
STANDARD_DEVIATION 5.6
Race (NIH/OMB)
American Indian or Alaska Native
4 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
10 Participants
Race (NIH/OMB)
More than one race
23 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
67 Participants
Sex: Female, Male
Female
38 Participants
Sex: Female, Male
Male
50 Participants
The Clinician-Administered Rating Scale for Mania (CARS-M)20.6 total score
STANDARD_DEVIATION 9.9

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 911 / 85
other
Total, other adverse events
0 / 910 / 85
serious
Total, serious adverse events
67 / 9177 / 85

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026